Clinicians have welcomed the Pharmaceutical Benefits Scheme (PBS) listing of the type 2 diabetes medicine that combines JARDIANCE® (empagliflozin) and TRAJENTA® (linagliptin) in a once-daily tablet
End of content
No more pages to load
Clinicians have welcomed the Pharmaceutical Benefits Scheme (PBS) listing of the type 2 diabetes medicine that combines JARDIANCE® (empagliflozin) and TRAJENTA® (linagliptin) in a once-daily tablet
End of content
No more pages to load